上尿路尿路上皮癌根治术后继发非肌层浸润性膀胱癌的BCG治疗效果
本研究观察了1463例接受根治性肾输尿管切除术的上尿路尿路上皮癌(UTUC)患者,其中256例(17%)后续发生非肌层浸润性膀胱癌(UTUC-NMIBC)。与原发性NMIBC相比,UTUC-NMIBC组在膀胱内BCG灌注后膀胱内复发预后更差,提示UTUC-NMIBC患者对BCG暴露固有反应较差。
要点
- UTUC根治术后17%(256/1463)患者继发NMIBC。
- 倾向性评分匹配后,UTUC-NMIBC组仅膀胱内复发预后较原发性NMIBC差。
- CUETO评分模型在UTUC-NMIBC组的验证显示预测复发和进展与实际存在显著差异。
核心结论
- 与原发性NMIBC组相比,UTUC-NMIBC组在接受膀胱内BCG治疗后预后更差,尤其是膀胱内复发。
- 这提示UTUC-NMIBC患者对BCG暴露固有反应较差。
研究设计与样本
- 观察性研究,纳入1463例接受根治性肾输尿管切除术的UTUC患者和1555例原发性NMIBC患者。
- 1463例UTUC患者中256例(17%)后续发生NMIBC(UTUC-NMIBC组)并纳入分析。
- 比较UTUC-NMIBC组与接受膀胱内BCG治疗的原发性NMIBC组的临床病理特征和结局,并进行倾向性评分匹配。
- 验证CUETO评分模型在UTUC-NMIBC组的效用,计算风险评分并与已发表的复发和进展概率比较。
主要发现
- 倾向性评分匹配前,UTUC-NMIBC组(n=75)与未调整的原发性NMIBC组(n=352)相比,膀胱内复发和进展预后更差。
- 倾向性评分匹配后,仅观察到UTUC-NMIBC组膀胱内复发预后更差。
- CUETO评分模型验证显示,在0-4分和5-6分评分组中,UTUC-NMIBC组与CUETO风险表参考数据的膀胱内复发率和进展率存在显著差异。
临床怎么用
- UTUC-NMIBC患者对BCG暴露可能反应较差,需建立最佳治疗策略和风险评分模型以选择辅助膀胱内BCG、化疗或立即根治性膀胱切除术的患者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the clinicopathological characteristics and prognosis of subsequent non-muscle-invasive bladder cancer (NMIBC) after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC), and particularly its response to intravesical Bacillus Calmette-Guérin (BCG). PATIENTS AND METHODS: An observational study was conducted in 1463 patients with UTUC who had undergone RNU and in 1555 patients with primary NMIBC. Of the 1463 patients with UTUC, 256 (17%) subsequently developed NMIBC (UTUC-NMIBC group) and were available for the analysis. The clinicopathological background and outcomes, including intravesical recurrence-free survival and bladder progression-free survival, were compared between the patients with UTUC-NMIBC and the patients with primary NMIBC treated with intravesical BCG. Propensity score matching was performed to adjust for the potential differences in the backgrounds of the two groups. To validate the utility of the CUETO scoring model in the UTUC-NMIBC group, risk scores were calculated and compared with the published probabilities for recurrence and progression. RESULTS: Compared with the unadjusted primary NMIBC group (n = 352), the UTUC-NMIBC group (n = 75) were found to have a worse prognosis for intravesical recurrence and progression, before propensity score matching. After propensity score matching for potential confounding factors, however, a worse prognosis was observed only for intravesical recurrence. The validation test of the CUETO scoring model for the UTUC-NMIBC group showed a significant difference in the rate of intravesical recurrence and progression for the 0-4 and 5-6 score groups between the UTUC-NMIBC group and the CUETO risk table reference data. CONCLUSION: Compared with the primary NMIBC group, the UTUC-NMIBC group had a worse prognosis after intravesical BCG, especially with regard to intravesical recurrence. This suggests that patients with UTUC-NMIBC are inherently poor responders to BCG exposure. An optimal treatment strategy and risk scoring model to select patients for adjuvant intravesical BCG, chemotherapy or immediate radical cystectomy should be established.
引用
- Miyake M, Tatsumi Y, Matsumoto H, et al. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma. BJU Int. 2018. PMID: 29281857. doi:10.1111/bju.14111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。